Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Assets (2019 - 2025)

Eton Pharmaceuticals' Assets history spans 7 years, with the latest figure at $104.5 million for Q3 2025.

  • For Q3 2025, Assets rose 191.59% year-over-year to $104.5 million; the TTM value through Sep 2025 reached $104.5 million, up 191.59%, while the annual FY2024 figure was $76.1 million, 139.83% up from the prior year.
  • Assets for Q3 2025 was $104.5 million at Eton Pharmaceuticals, up from $101.7 million in the prior quarter.
  • Across five years, Assets topped out at $104.5 million in Q3 2025 and bottomed at $21.5 million in Q3 2022.
  • The 5-year median for Assets is $30.9 million (2023), against an average of $41.6 million.
  • The largest annual shift saw Assets dropped 25.62% in 2022 before it surged 219.5% in 2025.
  • A 5-year view of Assets shows it stood at $27.5 million in 2021, then decreased by 8.87% to $25.0 million in 2022, then rose by 26.81% to $31.7 million in 2023, then soared by 139.83% to $76.1 million in 2024, then soared by 37.29% to $104.5 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Assets are $104.5 million (Q3 2025), $101.7 million (Q2 2025), and $84.0 million (Q1 2025).